Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impower-024: Islatravir as PrEP in MSM and TGW
NCT04652700Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Mar 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of islatravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experienced an Adverse Event (AE) During Blinded Treatment at 10.5 months and Number of Participants Who Discontinued From Blinded Study Treatment Due to an AE at 9 months. Started Mar 2021; status: terminated.
02
Drugs
islatravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04652700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04652700.